AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30614024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier transform infrared spectroscopy
Number of subjects: 0
Study 30614024 — intervention group
Group type: EXPERIMENTAL
Intervention: GC–MS analysis
Number of subjects: 0
Study 29153692 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum uterine curettage
Number of subjects: 442
Study 29153692 — intervention group
Group type: COMPARATOR
Intervention: No procedure (control)
Number of subjects: 442
Study 26139202 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + T-614 (50 mg/day for 24 weeks)
Number of subjects: 60
Study 26139202 — intervention group
Group type: COMPARATOR
Intervention: MTX (10 mg/week for first 4 weeks, then 12.5 mg/week for 20 weeks)
Number of subjects: 60
Study 23192164 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE sequence
Number of subjects: 17
Study 23192164 — intervention group
Group type: COMPARATOR
Intervention: MP-RAGE sequence
Number of subjects: 17
Study 21358422 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 40 Hz
Number of subjects: 12
Study 17382417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum digoxin concentrations (0.5-0.9 ng/ml)
Number of subjects: 4843
Study 17382417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4843
Study 16916871 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging reminder
Number of subjects: 993
Study 16916871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone reminder
Number of subjects: 993
Study 16916871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 993
Study 14520775 — intervention group
Group type: EXPERIMENTAL
Intervention: 19% sodium percarbonate film (Crest Night Effects) applied overnight
Number of subjects: 38
Study 14520775 — intervention group
Group type: COMPARATOR
Intervention: 18% carbamide peroxide gel (Colgate Simply White) applied twice daily
Number of subjects: 38
Study 10919929 — intervention group
Group type: COMPARATOR
Intervention: O(fat)
Number of subjects: 13
Study 10919929 — intervention group
Group type: EXPERIMENTAL
Intervention: O(cho)
Number of subjects: 13
Study 9365358 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial local anesthetic injection
Number of subjects: 19
Study 9365358 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 19
Study 1586077 — intervention group
Group type: EXPERIMENTAL
Intervention: EWLW management group (n=52)
Number of subjects: 101
Study 1586077 — intervention group
Group type: COMPARATOR
Intervention: Wedge pressure (WP) management group (n=49)
Number of subjects: 101
Study 3894125 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0
Study 3894125 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 0
Study 31300260 — intervention group
Group type: EXPERIMENTAL
Intervention: active intermittent theta burst stimulation (iTBS)
Number of subjects: 28
Study 31300260 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 28
Study 31300260 — intervention group
Group type: EXPERIMENTAL
Intervention: active iTBS
Number of subjects: 28
Study 29032294 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency Cg25 stimulation (130 Hz)
Number of subjects: 9
Study 29032294 — intervention group
Group type: COMPARATOR
Intervention: Low frequency Cg25 stimulation (20 Hz)
Number of subjects: 9
Study 27871575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 55 μg/kg
Number of subjects: 84
Study 27871575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil doses (0, 10, 20, 30, 40, 50, and 60 μg/kg)
Number of subjects: 84
Study 27871575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (various doses)
Number of subjects: 84
Study 24172057 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Number of subjects: 46
Study 24172057 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 46
Study 22775448 — intervention group
Group type: COMPARATOR
Intervention: Weekly Swedish massage
Number of subjects: 0
Study 22775448 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly Swedish massage
Number of subjects: 0
Study 22775448 — intervention group
Group type: COMPARATOR
Intervention: Light touch control
Number of subjects: 0
Study 21172026 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention for 12 weeks
Number of subjects: 127
Study 21172026 — intervention group
Group type: COMPARATOR
Intervention: Referral to community resources (Control)
Number of subjects: 127
Study 21172026 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention
Number of subjects: 127
Study 18201457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TA) 100 mg
Number of subjects: 30
Study 18201457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TA) 1 g
Number of subjects: 30
Study 18201457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results from TA groups (100 mg and 1 g)
Number of subjects: 30
Study 18201457 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 18201457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical epsilon‐aminocaproic acid (EACA)
Number of subjects: 30
Study 15744632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 0
Study 15744632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11999539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index diet (75 GI units)
Number of subjects: 45
Study 11999539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet (43 GI units)
Number of subjects: 45
Study 11999539 — intervention group
Group type: COMPARATOR
Intervention: Both high- and low-glycemic index diets
Number of subjects: 45
Study 9816716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (non-priming group, n = 20) - 0.25 mg/kg as a single intubating dose
Number of subjects: 60
Study 9816716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (priming group, n = 20) - 0.225 mg/kg preceded by 0.025 mg/kg 3 min earlier
Number of subjects: 60
Study 9816716 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (control group, n = 20) - 1 mg/kg as an intubating bolus
Number of subjects: 60
Study 7814828 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltoprazine
Number of subjects: 160
Study 7814828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 2700113 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day mepindolol (Group A)
Number of subjects: 19
Study 2700113 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day metoprolol duriles (Group B)
Number of subjects: 19
Study 2700113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 19
Study 2700113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beta-blockers (mepindolol and metoprolol)
Number of subjects: 19
Study 29460812 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (∼400 mg flavonoids, equivalent to 2-3 cups of tea)
Number of subjects: 20
Study 29460812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taste- and color-matched)
Number of subjects: 20
Study 27241836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aspirin supplementation
Number of subjects: 24
Study 27241836 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic aspirin supplementation
Number of subjects: 24
Study 27241836 — intervention group
Group type: COMPARATOR
Intervention: Aspirin supplementation
Number of subjects: 24
Study 24771721 — intervention group
Group type: COMPARATOR
Intervention: Control DDDR
Number of subjects: 1166
Study 24771721 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDRP + MVP
Number of subjects: 1166
Study 24771721 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP
Number of subjects: 1166
Study 24367492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 672
Study 24367492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 21405957 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg daily for 8 weeks) with ACE-I (perindopril)
Number of subjects: 66
Study 21405957 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg daily for 8 weeks) with thiazide (hydrochlorothiazide)
Number of subjects: 66
Study 21405957 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 66
Study 18626522 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg premedication
Number of subjects: 200
Study 18626522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16571846 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting a meal
Number of subjects: 24
Study 16571846 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding a meal
Number of subjects: 24
Study 16571846 — intervention group
Group type: COMPARATOR
Intervention: Control (usual four-meal pattern)
Number of subjects: 24
Study 14610410 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg bicalutamide
Number of subjects: 0
Study 11212479 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid cream applied in nostrils, 20 mg/gm, twice a day for four weeks
Number of subjects: 30
Study 9104518 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1A (portal injections with lidocaine, intraarticular lidocaine, placebo femoral nerve block)
Number of subjects: 60
Study 9104518 — intervention group
Group type: EXPERIMENTAL
Intervention: Group FNB (femoral 3-in-1 nerve block with chloroprocaine, placebo portal injections, placebo intraarticular saline)
Number of subjects: 60
Study 9104518 — intervention group
Group type: EXPERIMENTAL
Intervention: Group FNB + IA (femoral 3-in-1 nerve block, intraarticular lidocaine, placebo portal injections)
Number of subjects: 60
Study 9104518 — intervention group
Group type: COMPARATOR
Intervention: All groups (combined)
Number of subjects: 60
Study 1487923 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity Nautilus circuit training program (14 exercises, 30% of maximum) for six weeks, three times per week.
Number of subjects: 26
Study 1487923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 26
Study 3549871 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS stimulants (methylphenidate)
Number of subjects: 0
Study 31962052 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Relaxation (VRR)
Number of subjects: 255
Study 31962052 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 255
Study 30002346 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) treatment after exercise (-140 °C, 3 min)
Number of subjects: 12
Study 30002346 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) trial (rest period after exercise)
Number of subjects: 12
Study 30002346 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) treatment after exercise
Number of subjects: 12
Study 26400901 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization combined with stretching exercises (JM&Str)
Number of subjects: 43
Study 26400901 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection (SI)
Number of subjects: 43
Study 24881898 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of questionnaires (participate in research)
Number of subjects: 128
Study 24881898 — intervention group
Group type: COMPARATOR
Intervention: No participation in research (control)
Number of subjects: 128
Study 22265921 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP >1800 pg/mL
Number of subjects: 1086
Study 22265921 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP <150 pg/mL
Number of subjects: 1086
Study 22265921 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP (general correlation)
Number of subjects: 1086
Study 19720489 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose gadobutrol (0.1 mmol/kg b.w.)
Number of subjects: 16
Study 19720489 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose gadobutrol
Number of subjects: 16
Study 19720489 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose gadobenate-dimeglumine
Number of subjects: 16
Study 18375324 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.3 microg/kg/min, n = 45)
Number of subjects: 90
Study 18375324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 90
Study 16568409 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training (twice-weekly)
Number of subjects: 86
Study 16568409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 12666710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse (15 ml, 30 seconds)
Number of subjects: 80
Study 12666710 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse (10 ml, 60 seconds)
Number of subjects: 80
Study 12666710 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire results for taste perception, duration of taste, alteration in taste, perceived plaque reduction
Number of subjects: 80
Study 10607709 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0
Study 10607709 — intervention group
Group type: COMPARATOR
Intervention: Untreated HIV-1 infection
Number of subjects: 0
Study 9194621 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intravenous magnesium sulfate therapy
Number of subjects: 0
Study 9194621 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers not receiving magnesium sulfate)
Number of subjects: 0
Study 1535083 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY u 3405 (20 mg orally 1 hour before challenges)
Number of subjects: 12
Study 1535083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3032562 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 10 mg orally
Number of subjects: 12
Study 3032562 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 5 mg intravenously
Number of subjects: 12
Study 3032562 — intervention group
Group type: EXPERIMENTAL
Intervention: enalaprilat 5 mg intravenously
Number of subjects: 12
Study 3032562 — intervention group
Group type: COMPARATOR
Intervention: enalapril (oral and intravenous) and enalaprilat (intravenous)
Number of subjects: 12
Study 31837719 — intervention group
Group type: EXPERIMENTAL
Intervention: Close relationships with students
Number of subjects: 0
Study 31837719 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflictual relationships with students
Number of subjects: 0
Study 28660640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir (SOF/LDV) for 12 weeks
Number of subjects: 196
Study 28660640 — intervention group
Group type: COMPARATOR
Intervention: Pegylated‐IFN/Ribavirin (RBV)
Number of subjects: 196
Study 26277355 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed IV fluids
Number of subjects: 126
Study 26277355 — intervention group
Group type: COMPARATOR
Intervention: Room temperature IV fluids
Number of subjects: 126
Study 23213082 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative occupational therapy intervention
Number of subjects: 60
Study 23213082 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 21577124 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol-400 (Iomeron, Bracco Imaging SpA, Milan, Italy)
Number of subjects: 96
Study 21577124 — intervention group
Group type: COMPARATOR
Intervention: iodixanol-320 (Visipaque, GE Healthcare, Chalfont St. Giles, United Kingdom)
Number of subjects: 96
Study 21577124 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol-400
Number of subjects: 96
Study 21577124 — intervention group
Group type: COMPARATOR
Intervention: iodixanol-320
Number of subjects: 96
Study 19300369 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD+CAF
Number of subjects: 12
Study 19300369 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG+CAF
Number of subjects: 12
Study 16814225 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal knee-chest posture
Number of subjects: 25
Study 16814225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 15646221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: filled with two horizontal increments
Number of subjects: 30
Study 15646221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: filled with two horizontal increments, first up to half cavity height and light cured using a transparent plastic cone (Cerana), second filling remainder of cavity
Number of subjects: 30
Study 15646221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: filled in the same way as Group 2, except first increment only filled one‐third of cavity height
Number of subjects: 30
Study 11158452 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dexamethasone treatment
Number of subjects: 570
Study 11158452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 570
Study 11158452 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dexamethasone
Number of subjects: 570
Study 11158452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 570
Study 11158452 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide
Number of subjects: 570
Study 11158452 — intervention group
Group type: COMPARATOR
Intervention: Delayed selective treatment
Number of subjects: 570
Study 9242847 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach treatment
Number of subjects: 50
Study 9242847 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 50
Study 8112550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 119
Study 8112550 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination
Number of subjects: 119
Study 3298406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (thrice weekly for 6 months after a 5-day induction phase)
Number of subjects: 32
Study 3298406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon
Number of subjects: 32
Study 3298406 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 32
Study 30348206 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline supplemented with pregabalin
Number of subjects: 392
Study 30348206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin supplemented with amitriptyline
Number of subjects: 392
Study 30348206 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine supplemented with pregabalin
Number of subjects: 392
Study 30348206 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 392
Study 26763030 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 0
Study 26763030 — intervention group
Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 0
Study 24219399 — intervention group
Group type: EXPERIMENTAL
Intervention: Core disgust stimuli
Number of subjects: 0
Study 24219399 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful injuries
Number of subjects: 0
Study 24219399 — intervention group
Group type: COMPARATOR
Intervention: Neutral scenes
Number of subjects: 0
Study 23213979 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) and Zusanli (ST 36)
Number of subjects: 240
Study 23213979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolantin
Number of subjects: 240
Study 23213979 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 240
Study 20556258 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implants (n = 75)
Number of subjects: 36
Study 20556258 — intervention group
Group type: COMPARATOR
Intervention: Nonplatform-switched implants (n = 14)
Number of subjects: 36
Study 18609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based assessment (BIA)
Number of subjects: 0
Study 18609248 — intervention group
Group type: COMPARATOR
Intervention: Standard assessment (SA)
Number of subjects: 0
Study 16150764 — intervention group
Group type: EXPERIMENTAL
Intervention: Social behaviour and network therapy
Number of subjects: 742
Study 16150764 — intervention group
Group type: COMPARATOR
Intervention: Motivational enhancement therapy
Number of subjects: 742
Study 12020739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (360 mg)
Number of subjects: 20
Study 12020739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (400 mg)
Number of subjects: 20
Study 12020739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo/ginseng combination (960 mg)
Number of subjects: 20
Study 12020739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10071829 — intervention group
Group type: EXPERIMENTAL
Intervention: Narpan (generic naltrexone)
Number of subjects: 12
Study 10071829 — intervention group
Group type: COMPARATOR
Intervention: Trexan (innovator product)
Number of subjects: 12
Study 7560624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase
Number of subjects: 469
Study 7560624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 2076318 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 5
Study 2076318 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxyciclin + clavulanic
Number of subjects: 5
Study 2076318 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone‐iodine
Number of subjects: 5
Study 2076318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6101739 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (T4 to S5)
Number of subjects: 12
Study 6101739 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 12
Study 6101739 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 12
Study 30624753 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 0 mg Zn/sachet
Number of subjects: 74
Study 30624753 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 5 mg Zn/sachet
Number of subjects: 74